Organon Agrees to All-Cash Acquisition by Sun Pharma

Organon ( (OGN) ) has issued an update.

On April 26, 2026, Organon agreed to be acquired by an affiliate of Sun Pharmaceutical Industries in an all-cash merger valuing the women’s health and general medicines specialist at US$11.75 billion, or US$14.00 per share, a 103% premium to its unaffected April 9, 2026 close, with closing targeted for early 2027 subject to shareholder and regulatory approvals. The deal will take Organon private and off the NYSE, reshapes Sun Pharma into a stronger global force in branded generics, women’s health and biosimilars, and includes detailed cash-out and rollover treatment for equity awards, a US$120 million termination fee framework, and leadership continuity as interim CEO Joseph Morrissey and interim executive chair Carrie Cox were both confirmed in their roles on a permanent basis the same day.

The transaction is positioned to accelerate Sun Pharma’s growth strategy, with Organon’s portfolio and 140-country footprint expected to help vault the buyer into the top 25 global pharma companies by revenue and nearly double combined EBITDA and cash flow, improving leverage. For Organon’s shareholders, the board’s endorsement of the premium cash offer provides immediate value but also locks in a path to loss of public-market upside, while employees and other stakeholders face a transition in ownership under a structure that preserves key long-term incentive plans but subjects the company to integration, regulatory and closing risks over a timeline that could extend to January 2027.

The most recent analyst rating on (OGN) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Organon stock, see the OGN Stock Forecast page.

Spark’s Take on OGN Stock

According to Spark, TipRanks’ AI Analyst, OGN is a Neutral.

The score is held down primarily by weakened profitability and high leverage despite solid cash generation. Technicals are supportive with the stock above major moving averages, but overbought indicators raise near-term risk. Valuation is relatively low on P/E, while earnings-call guidance suggests flat fundamentals with ongoing margin and execution headwinds.

To see Spark’s full report on OGN stock, click here.

More about Organon

Organon & Co. is a global healthcare company spun off from Merck in 2021, focused on women’s health and general medicines, including biosimilars. Its portfolio of more than 70 products is sold in over 140 countries, with major markets in the U.S., Europe, China, Canada and Brazil, supported by six manufacturing facilities across the EU and emerging markets.

Headquartered in Jersey City, New Jersey, Organon positions itself as a leader in women’s health while expanding access and affordability of essential treatments worldwide. The company’s legacy of strong brand equity and trusted relationships with healthcare providers and regulators underpins its strategy and market presence.

On April 26, 2026, Organon agreed to be acquired by Sun Pharmaceutical Holdings USA, an affiliate of India’s Sun Pharmaceutical Industries, in an all-cash merger valuing Organon at US$11.75 billion, or US$14.00 per share, a 103% premium to its unaffected April 9, 2026 closing price. The deal, which will take Organon private and lead to its NYSE delisting once completed, is backed by committed debt financing and requires shareholder and global antitrust and FDI approvals, with closing targeted for early 2027.

Under the merger terms, Organon stockholders will receive cash for their common shares, while stock options that are in the money will be cashed out and underwater options cancelled. Pre-2026 restricted and performance stock units will vest and convert into cash at closing, whereas later grants will roll into cash-based awards under Sun Pharma with similar service-based vesting, aligning employee incentives during the transition.

The transaction is designed to bolster Sun Pharma’s established brands and branded generics franchise, make it a top-three global women’s health player and the world’s seventh-largest biosimilars company, and nearly double combined EBITDA and cash flow, improving leverage metrics. For Organon investors, the board highlighted the immediate, compelling value of the cash offer, while deal protections include a no-shop clause, matching rights and a US$120 million termination fee if Organon accepts a superior proposal.

The merger remains subject to a majority vote of Organon shareholders, U.S. Hart-Scott-Rodino clearance, non-U.S. antitrust and foreign investment approvals and the absence of a material adverse effect or prohibitive legal orders, with a long-stop date of January 26, 2027. If completed, Organon will become a wholly owned subsidiary of Sun Pharma; both sides have outlined extensive regulatory covenants and affiliate guarantees to support execution amid potential competing bids and regulatory risks.

Alongside the deal announcement, Organon finalized key leadership decisions on April 26, 2026, confirming Joseph Morrissey as permanent chief executive officer after serving in an interim capacity since October 26, 2025. The company also made Carrie S. Cox, who had been interim executive chair since October 26, 2025, its executive chair on a non-interim basis, with no changes to the compensation arrangements for either executive.

Average Trading Volume: 5,839,163

Technical Sentiment Signal: Buy

Current Market Cap: $2.93B

Learn more about OGN stock on TipRanks’ Stock Analysis page.